Haemolytic disease of the fetus and newborn (HDFN) is a severe disease in which fetal red blood cells (RBC) are destroyed by maternal anti-RBC IgG alloantibodies. HDFN is most often caused by anti-D but may also occur due to anti-K, -c-or -E. We recently found N-linked glycosylation of anti-D to be skewed towards low fucosylation, thereby increasing the affinity to IgG-Fc receptor IIIa and IIIb, which correlated with HDFN disease severity. Here, we analysed 230 pregnant women with anti-c, -E or -K alloantibodies from a prospective screening cohort and investigated the type of Fc-tail glycosylation of these antibodies in relation to the trigger of immunisation and pregnancy outcome. Anti-c, -E and -K show -independent of the event that had led to immunisation -a different kind of Fc-glycosylation compared to that of the total IgG fraction, but with less pronounced differences compared to anti-D. High Fc-galactosylation and sialylation of anti-c correlated with HDFN disease severity, while low anti-K Fc-fucosylation correlated with severe fetal anaemia. IgG-Fc glycosylation of anti-RBC antibodies is shaped depending on the antigen. These features influence their clinical potency and may therefore be used to predict severity and identify those needing treatment.
Haemolytic disease of the fetus or newborn (HDFN) is a potentially life-threatening disease in which red blood cells (RBC) of the infant are destroyed by maternally derived RBC alloantibodies, resulting in fetal/neonatal anaemia and/or neonatal hyperbilirubinaemia, in some cases leading to hydrops, perinatal death or kernicterus (Deng et al, 2008; Kamphuis et al, 2008; Moise, 2008) . The most clinically relevant RBC alloantibodies in pregnant women are anti-D, E, c and K (Koelewijn et al, 2008a; Moise, 2008; Goldman et al, 2015) . The widespread introduction of anti-D immunoglobulin has decreased the incidence of alloimmunisation against D in pregnant women. In the Netherlands, for example, the prevalence of RhD-antibodies is currently about 0Á1% of all pregnant women (Koelewijn et al, 2008b) . The prevalence of clinically relevant non-RhD antibodies is 0Á328%, with anti-E, -c and -K antibodies being the most frequent (0Á095%, 0Á050% and 0Á079% respectively) (Koelewijn et al, 2008a) .
In a prospective cohort of 900 pregnant women with nonRh alloantibodies, anti-K showed the highest risk for severe HDFN (i.e. the need for a fetal or neonatal (exchange) blood transfusion) (26%), followed by anti-c (10%) and other Rh (non-D) antibodies (3%) (Koelewijn et al, 2008a) . For comparison, the risk for severe HDFN in D-positive children of D immunised mothers is about 30% (Koelewijn et al, 2008b) . Antibodies against other blood group specificities only rarely cause severe HDFN (Koelewijn et al, 2008b) .
In alloimmunised pregnancies, the pathological mechanism underlying fetal anaemia is haemolysis, which occurs after binding of the IgG-sensitised RBC to the Fcc Receptors (FccRs) of effector cells in the spleen and liver. In anti-Kmediated HDFN however, fetal anaemia may also be caused by suppression of erythropoiesis, possibly by phagocytosis, rather than by haemolysis of RBC (Vaughan et al, 1998) , and is likely to be mediated by other effector cells (Daniels et al, 2003) .
After the detection of clinically relevant RBC alloantibodies, pregnancies at high risk for fetal haemolysis can be identified by determining the antibody titres; although anti-K antibody at any titre may be considered potentially clinically significant . To increase the diagnostic accuracy of detection of high-risk pregnancies in The Netherlands, the antibody dependent cellular cytotoxicity (ADCC) test is also performed to assess the ability of these antibodies to cause haemolysis (Oepkes et al, 2001; de Haas et al, 2015) . Fetal anaemia can be determined via Doppler flow measurements, a non-invasive approach measuring the middle cerebral artery peak systolic velocity with a sensitivity and specificity of 88% and 82%, respectively (Oepkes et al, 2006; Moise & Argoti, 2012) .
There is no strict correlation between the amount of the pathological RBC alloantibodies and HDFN disease severity. It is likely that biochemical-properties of RBC alloantibodies, such as affinity, isotype, subclass or post-translational modifications are of influence (Oepkes et al, 2001; de Haas et al, 2015; Sonneveld et al, 2016a) . Predominantly by clinical applications of monoclonal antibody (mAb) therapies, we have recently learned the importance of IgG-glycosylation for its function (Mizushima et al, 2011; Zheng et al, 2011) . IgG contains one highly conserved N-linked glycosylation site in the Fc part at position Asn 297. This glycan contains an invariant core structure of four N-acetylglucosamines (GlcNAc) and three mannoses. In addition, a core fucose, a bisecting GlcNAc (bisection) and one or two galactoses and/ or N-acetylneuraminic (sialic) acids can be attached. A lack of fucose moiety is known to increase the binding affinity to FccRIIIa (monocyte, natural killer cell) and FccRIIIb (granulocyte), enhancing the destruction of the target cell (Ferrara, et al 2011 , Kapur et al, 2014 . Therefore the target cell is employed to enhance the efficacy of anti-cancer antibodies (Sonneveld et al, 2016a) . In addition, galactoses and sialic acids have been proposed to convey anti-inflammatory properties in mouse models (Anthony & Nimmerjahn, 2011; Karsten et al, 2012) , although this has been heavily debated . The functional consequences, if any, of bisecting GlcNAc are not fully understood yet.
We recently found that IgG1-responses against platelet antigens and RhD on RBCs can be particularly skewed towards IgG with low core-fucosylation (Wuhrer et al, 2009; Kapur et al, 2014; Sonneveld et al, 2016b) , a feature that has only previously been described for anti-human immunodeficiency virus (HIV) antibodies, but never for any other immune response (Ackerman et al, 2013) . This is reflected in total serum IgG-Fc having~94% fucose on the glycopeptide level (Selman et al, 2012; Fokkink et al, 2014; Vestrheim et al, 2014) . The lowered core-fucosylation of both anti-D and anti-Human Platelet Antigen (HPA)-1a platelet antibodies correlated with severity of disease in patients with HDFN or fetal or neonatal alloimmune thrombocytopenia (FNAIT) (Kapur et al, 2014) . A subsequent study on FNAIT identified galactosylation as an additional marker that, together with fucosylation and antibody level, predicted the clinical outcome (Sonneveld et al, 2016b) . These associations were found despite the retrospective set-up of the sampling. In the absence of screening of FNAIT, only cases with affected children could be sampled, often with prenatal interventions, making it impossible to compare affected with asymptomatic individuals. In this study we aimed to investigate, in a prospective cohort of 230 alloimmunised pregnancies, whether this skewed glycosylation pattern also applies to anti-c, anti-E and anti-K antibodies and whether skewing of glycosylation is dependent on the trigger of alloimmunisation upon a blood transfusion or pregnancy. Hypothesizing that all alloantibodies against RBCs show a similar skewing in glycosylation as we found for anti-D, we also tested if alloantibody glycosylation in this prospective cohort is associated with clinical outcome in anti-c, -E and -K mediated HDFN.
Methods

Patient samples
Patient samples and clinical data from the prospective OPZI study (Detection and Prevention of Pregnancy Immunisation) were included after informed consent (Koelewijn et al, 2008a (Koelewijn et al, , 2009 (Koelewijn et al, 2008a (Koelewijn et al, , 2009 ). None of the affected cases received intravenous immunoglobulin therapy. Clinical data (haemoglobin levels and treatment with phototherapy or blood transfusion) were collected via healthcare workers (Koelewijn et al, 2008a) . The route of immunisation was defined as being either transfusion (having an antigen-negative partner or being nulliparous and a blood transfusion in the medical history), or pregnancy-based (antigen-positive partner, parous, without blood transfusion in medical history). Clinical outcome was categorized based on received treatment by the newborn in three groups: (i) severe (defined by an intrauterine or post-delivery blood transfusion given to the fetus or newborn, respectively), (ii) moderate (phototherapy was given to the newborn), or (iii) healthy (no treatment given to the newborn).
Purification of IgG from sera and eluates
Total and antigen-specific IgG alloantibodies were purified using protein G Sepharose 4 Fast Flow beads (GE Healthcare Life Sciences, Uppsala, Sweden) in a 96-well filter plate (Orochem, Naperville, IL, USA) as described previously (Kapur et al, 2014) .
Mass spectrometric IgG-Fc glycosylation analysis
Analysis of purified tryptic IgG Fc-glycosylation was performed with nanoLC-reversed phase (RP)-electrospray (ESI)-ion trap (IT)-mass spectrophotometry (MS)(/MS) on an Ultimate 3000 RSLCnano system (Dionex/Thermo Scientific, Breda, the Netherlands) coupled to an amaZon speed ESI-IT-MS (Bruker Daltonics, Bremen, Germany). In the current study we focused on IgG1, without analysing IgG3 due to its possible interference with IgG2 at the glycopeptide level (Einarsdottir et al, 2013) . Mass spectrometry results were found reliable, given that the sum of the signal intensity of all glycopeptide species divided by the background was above 100. Otherwise the data was excluded. Further details are described in the Data S1.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 6.00 for Windows (GraphPad Software Inc., La Jolla, CA, www.graphpad.com) and IBM SPSS Statistics for Windows version 21.0 (IBM Corp., Armonk, NY, USA).
The level of significance was set at P < 0Á05 using twotailed tests.
Results
Fc glycosylation of anti c, E and K in HDFN is different compared to that of anti D
To investigate the Fc glycopeptides of total-and antigen-specific-IgG1 alloantibodies (Fig 1) , 230 serum samples of women with anti E, c or K were analysed by mass spectrometry. For 143 women we succeeded in obtaining both RBC antigen-specific IgG1 Fc glycosylation profiles and profiles of a serum IgG1 fraction (Fig 2) .
The Fc-glycoprofiles of purified anti-c, E and K IgG1 were compared in a pairwise manner with that of serumderived IgG1 with respect to bisection, galactosylation, sialylation and fucosylation (Fig 3) . Glycoforms with bisection were slightly but significantly decreased only for antic (from 15Á1% to 10Á2% for total vs. c-specific IgG, respectively; P < 0Á0001). Similarly, glycoforms of anti-c showed slightly higher levels of galactosylation (74Á4%) compared to total IgG (70Á1%, P = 0Á039), as was also found for anti-E (72Á0% vs. 69Á9%, P = 0Á023), but not for anti-K (70Á1% vs. 71Á4%, P = 0Á345). No consistent alteration in sialylation was found. Anti-c fucosylation was not significantly altered (92Á5% vs. 92%, P = 0Á475), but strongly decreased levels of fucosylation down to 63% were observed in a few individual anti-c cases. Although anti-E fucosylation was significantly decreased (P = 0Á041), the average levels were close to the level of fucosylation of serum-derived IgG (92Á6% vs. 91Á4%). Anti-K fucosylation showed the most striking changes, with fucosylation levels for the anti-K being down to 30% with a geometric mean of 74% (P = 0Á0127) (Fig 3A) .
We then compared the glycoform profiles of anti-c, E and K (depicted as the ratio of specific IgG glycosylation divided by the total glycosylation) with that of anti-D, as published by Kapur et al (2014) (Fig 3B) . The relative decrease in bisection was most pronounced for anti-D (mean 0Á33) compared to c (0Á75), E (1Á04) and K (1Á05) (P < 0Á0001). The galactosylation ratio for anti-D was significantly higher (1Á43) compared to the other three RBC alloantibody specificities (P < 0Á0001). However, galactosylation did not differ significantly between anti-c, E and K (1Á05, 1Á04 and 1Á03 respectively). Notably, lowered fucosylation was most pronounced for anti-D (0Á56) compared to all other specific antibodies measured (P < 0Á005), although anti-K also showed a lowered ratio (0Á84; Fig 3B) .
Fc-glycosylation is not dependent on the event that induced immunisation
To analyse the effect of the route of immunisation we compared, within the anti-E and anti-K cohorts, the women in whom the alloantibody was induced by transfusion (defined by blood transfusion in the medical history, having a K-negative partner or being nulliparous) (E: n = 5, K: n = 10) with those immunized by pregnancy (no blood transfusion in medical history, parous, K-positive partner) (E: n = 3, K: n = 10). No differences were found between the transfusionand pregnancy-induced antibodies for fucosylation, bisection, galactosylation or sialylation (Fig 4) .
Fc-glycosylation correlates with disease severity
Of the 143 mothers with RBC alloantibodies, 100 gave birth to an antigen-positive newborn (K: n = 11, c: n = 56, E: n = 33), making them at risk for HDFN (Table SI) . Severe HDFN was diagnosed in 13 children, 24 children were diagnosed with moderate HDFN and 63 without HDFN (Fig 2) . The average Hb level in children with anti-K, anti-c or anti-E complicated pregnancies was 130Á5, 141Á8 and 153Á1 g/l, respectively. None of the controls or antigen-negative children was diagnosed with severe HDFN, although 4% received phototherapy (Fig 2) (Koelewijn et al, 2008b) . Controls and antigen-negative children had a mean Hb level of 154Á7 g/l (Koelewijn et al, 2008b) .
No correlation was found between anti-c glycosylation and haemoglobin level (Fig 5A) . However, based on the treatment given to the newborn, anti-c galactosylation and Antibody specific sialylation
T r a n s f u s i o n E P r e g n a n c y E T r a n s f u s i o n K P r e g n a n c y No difference between pregnancy-and transfusion-induced IgG1 glycosylation. The antibody-specific bisection, galactosylation, sialylation and fucosylation (y-axis) depicted for all anti-K and anti-E antibodies elicited after either transfusion or pregnancy (x-axis).
Statistical analysis was performed using the Mann-Whitney U test and Kruskal-Wallis test.
sialylation was found to be associated with disease severity (P = 0Á008 and P = 0Á039 respectively, Kruskal Wallis test) (Fig 5B) . Furthermore, to predict fetal/neonatal disease (treatment with blood transfusion or phototherapy) we included antibody level, galactosylation, sialylation, bisection and fucosylation of anti-c in a stepwise forward procedure as covariates in a multivariate logistic regression analysis. Including all covariates gave the strongest model, predicting 77% of the outcome (Nagelkerke Chisquare), with antibody level (P = 0Á035) and fucosylation (P = 0Á038) being the strongest covariates. Goodness of fit test showed no evidence for lack of fit (Hosmer Lemeshow test P = 0Á601). Due to the low sample size, stepwise forward multiple regression analysis was not possible for anti-K. We performed Spearman rank analysis with the 11 anti-K pregnancies and Hb level. The levels of fucosylation and bisection were significantly associated with haemoglobin level (Spearman's r = 0Á682, P = 0Á025 and r = 0Á691, P = 0Á023 respectively) (Fig 6A) . The same trends were found between glycosylation of anti-K and disease severity although this was only borderline significant (Fig 6B) .
In accordance with the no-or limited skewing in anti-E glycosylation, no correlations were found between anti-E glycosylation and the available clinical parameters (Fig S1) .
Discussion
We determined IgG1 Fc-glycosylation profiles of RBC alloantibodies purified from blood samples from 177 alloimmunised pregnant women using mass spectrometry and compared them to the glycosylation pattern of anti-D, previously determined (Kapur et al, 2014) . Similar to the anti-D antibodies, the glycosylation patterns of anti-c, E and K differed markedly from the total IgG-glycosylation, but also from each other, with each type of antibody-specificity having a unique pattern. A correlation between the various Fc-tail glycoforms and HDFN severity was observed.
We have previously shown that anti-D alloantibodies show markedly decreased fucosylation, down to 30%, leading to increased affinity to FccRIIIa (and FccRIIIb). A lower core fucosylation was associated with increased disease severity (Kapur et al, 2014) , a feature we also found for anti-HPA-1a antibodies in FNAIT (Kapur et al, 2014; Sonneveld et al, 2016b) . We hypothesized that all RBC alloantibody specificities would show a similar skewing in fucosylation. However, the other (less pathogenic) Rh antibodies showed no (anti-c) or far less (anti-E) excessive skewing of fucosylation. This might be partly explained by the prospective setup of the current study. However, a similar skewing was observed for anti-K fucosylation as for anti-D. This argues against the possibility that the different glycosylation patterns are explained by the way of sampling.
Similarly, we also found differences in bisection and galactosylation between the different antibody specificities, suggesting that RBC antigens have different tendencies to promote antibody responses with certain glycosylation features. We previously found an increased level of galactosylation of anti-HPA-1a (Kapur et al, 2014; Sonneveld et al, 2016b) and RhD (Kapur et al, 2014) as compared with total IgG1. As both alloantibodies were developed during pregnancy, where total IgG-galactosylation is known to be increased in general (Ruhaak et al, 2014) , we hypothesized that this shifting might be influenced by pregnancy. However, although antigen-specific IgG1 galactosylation was significantly increased for anti-c and -E, this was much less prominent than we described for RhD. Anti-K IgG1 galactosylation was even unchanged, arguing against the possibility that pregnancy is the determining factor stimulating enhanced galactosylation. In addition, no differences in glycosylation patterns between pregnancy and transfusion-derived antibody glycosylation patterns were seen, again indicating pregnancyinduced immune responses are not a driving factor for the particular glycosylation seen in these antibodies. This is in line with previous results where a downward skewing of Fcfucosylation was also observed in male hyperimmunised anti-D donors (Kapur et al, 2015) .
In the present study, a decreased fucosylation of anti-K specific antibodies was found to correlate with the haemoglobin level. This reinforces the theory that there is a link between antibody-specific glycosylation, FccRIIIa/FccRIIIb binding and hence, cell breakdown (Karsten et al, 2012; Kapur et al, 2015) . As we did not find a major skewing of fucosylation for anti-c, a potential effect of fucosylation on disease severity might have been missed. Indeed, the two cases with clearly lowered fucosylation levels belonged to the only nine out of 69 anti-c cases showing severe disease (defined as blood transfusion given to the newborn). In addition, we found fucosylation to be a significant variable in predicting severe disease for anti-c in multivariate analysis.
We found that an increased galactosylation and sialylation of anti-c specific antibodies was also associated with the level of HDFN severity, suggesting that besides fucosylation, other glycosylation features may also influence phagocytosis. This is in line with recent studies showing a positive correlation between galactosylation and the binding of IgG1 to FccRIIIa and FccRIIIb, ADCC activity (Houde et al, 2010; Thomann et al, 2015) and clinical outcome in FNAIT (Sonneveld et al, 2016b) . No major effect of sialylation on binding to FccR has been reported in the literature. This suggests that the positive correlation between sialylation and severity may be indirect and due to the strong association between galactosylation and sialylation. Galactosylation or sialylation did not show a correlation with clinical outcome for anti-K specific antibodies, which is in line with the lack of changes for these glycosylation features in anti-K responses.
No correlation between glycosylation and clinical parameters was found for anti-E. This was to be expected because the presence of anti-E rarely leads to clinical consequences (Koelewijn et al, 2008a) .
Moreover, we only found minimal skewing of anti-E glycosylation, making it unlikely that a correlation with clinical parameters would be found and again strengthening the suggestion that pathogenic glycosylation patterns are required for developing HDFN.
Mass spectrometric methods for the analysis of protein modifications in general and antibody Fc glycosylation in particular are envisioned to gain importance in clinical settings in the coming years. In this respect, it should be mentioned that antibody Fc glycosylation analysis by mass spectrometry has taken an important step towards its implementation in clinical chemistry as it has already been demonstrated on systems that are routinely found in clinical chemistry laboratories, i.e., triple quadrupole mass spectrometers with analytical-scale high performance liquid chromatography systems (Ruhaak & Lebrilla, 2015) . Moreover, standardized, robust sample preparation platforms are finding a place in IgG glycosylation analysis -be it for MS or fluorescence detection, and in glycomics, mass spectrometry is becoming an attractive alternative to separation methods with fluorescence detection (Huffman et al, 2014; Varadi et al, 2014) . Notably, the implementation of internal standards allowing absolute quantitation is another important contribution towards the broader and routine use of MS for clinical glycomics and IgG Fc glycosylation analysis (Stavenhagen et al, 2013; Echeverria et al, 2015) . Although these methods are highly sensitive, the analysis of antigen-specific antibodies will always be limited by the antibody levels. Low antibody levels, certainly in combination with low affinity, will result in low and unreliable signals. This was also a limitation in the current study, as 74 (29%) samples did not fulfil our criteria for reliable signals.
Other factors, such as the RBC antibody titre, and antigenexpression during RBC-development have influence on cell breakdown. This is particularly true for the Kell glycoprotein, which, unlike the Rh proteins, is expressed early during erythropoiesis. The type of effector cells involved in the clearance of either erythroid progenitor, probably originating from the bone-marrow, or RBC themselves, probably in the spleen and liver, will also influence this complex picture, probably because they are equipped with different patterns of FccRs.
In conclusion, our current knowledge implies that pregnant women with high antibody levels combined with low fucosylation and high galactosylation are at risk for developing HDFN. This prospective study shows that RBC antigens differ in type of antibody response with different Fc-glycosylation patterns. However, despite less skewing in Fcglycosylation, the clinical outcome of HDFN is affected by IgG1-glycosylation. The interplay between differently glycosylated IgGs and Fc-receptors is proving to become an important biomarker in screening for pathological IgGs, particularly for HDFN and FNAIT because of the vastly diverse fucosylation and galactosylation levels seen in these immune responses.
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